On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will likely in no way disappear and a vaccine will not stop it totally. He also stated that ministers and specialists must cease ‘over-promising’ and be realistic about the prospects of a vaccine and the most likely timeline of one, unlikely prior to spring subsequent year.
He then echoed his earlier warnings and those of his colleague Professor Chris Whitty that the COVID-19 fight will be a lengthy 1, and it will be with us for excellent.
So, from this really should we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there had been a single therapy that:
could cease the infection in its tracks,
was anti-inflammatory controlling the immune system’s response to the infection and stopping it from overreacting dangerously,
in instances where patients developed secondary bacterial infections in the lungs could supercharge antibiotics boosting their efficacy and eve,
was a repurposed drug currently proven as safe
was straightforward to make, scalable at the level needed to make a difference in the pandemic and was price productive, then would not that be one thing we ought to all be acquiring excited about?
Surely though no such ‘silver bullet’ game altering therapy exists? Following all, the only treatment options we hear about for COVID are these which President Trump took, which have been either incredibly new, pricey and experimental or have a extremely narrow application to a distinct aspect of the disease.
Well, you heard it here 1st – such a ‘silver bullet’ treatment does exist now. It really is named Nylexa®, from the tiny UK biotech company NovaBiotics Ltd. It is active ingredients have been safely applied in medicines that treat unrelated circumstances for more than 30 years.
NovaBiotics found Nylexa’s potential advantages in COVID-19 following a decade of investigation in complicated to treat, drug-resistant infections, including the complex chest infections and inflammation connected with cystic fibrosis (CF) lung disease. In March they applied for a £1m grant from Innovate UK (representing the government) to start out clinical studies. That grant was at some point awarded earlier this month, and the government are now taking into consideration no matter if or not to involve Nylexa on two separate NHS platform research.
But why, I hear you ask, if this is so good have we not heard about it just before? Why are the government and the press not shouting about this from the rooftops? Why is this not being demanded by clinicians desperate for powerful treatment options for their individuals?
I’m afraid to say, it all boils down to revenue. Tiny biotech providers locate it tricky to get attention as they never have the resources accessible to their bigger far better funded rivals. The names we study about consistently when it comes to ground breaking new therapies are invariably huge multi-national pharmaceutical corporations with deep pockets and massive budgets to promote their own unique wares. They make sure their drugs get the expected attention. covid testing chicago is a modest private company funded by a group of loyal and supportive shareholders so however never have the sources to compete for interest with the major boys.
Which is why this predicament is so frustrating. In mitigating the overall health consequences of contracting COVID-19, Nylexa® could raise public confidence of living with the virus for the longer term and potentially allow a greater degree of normality to return to the way in which we reside, benefiting the economy straight in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. However having men and women in positions of influence to take notice amongst all the other folks competing for their attention is pretty difficult certainly.
It is reported that there are thousands of prospective COVID-19 remedies in clinical trials across the planet. I would challenge any one to show me a single which has the identical possible for constructive influence as Nylexa®, however this is not at present component of any trial, in spite of its impeccable credentials. So come on UK Government, and ministers, get your finger out and get this drug into trials right away. The sooner it gets tested, the sooner it can be employed to support sort out the mess the pandemic has triggered to all our lives.
About NovaBiotics Ltd
NovaBiotics Ltd is a clinical-stage biotechnology company focused on the style and development of first-in-class therapies for hard-to-treat, medically unmet infectiousdiseases brought on by bacteria and fungi and respiratory situations which includes cystic fibrosis and COVID-19.
A major innovator in the anti-infectives space, the Company’s robust technologies and business model has been validated by means of prosperous development, from idea to late stage clinical development, of its most advanced item candidates. In addition to the lead Nylexa® programme and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, higher-value drug candidates such as NP339 (Division of Well being and Social Care funded programme) for life threatening, drug resistant invasive fungal illness and NP432 for multi- drug resistant bacterial infections.